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PURPOSE: To assess the hemostatic responses to exercise in a patient with 
Polycythemia Vera (PV). METHODS: Six female runners (≥15 miles/week) completed a 
maximal treadmill test. One subject had PV while the other five subjects made up the 
comparison group. Blood samples were taken before and within two minutes after 
exercise. VO2max was also recorded. RESULTS: Pre-exercise Factor VIII and tPA-
antigen were similar in the PV subject and comparison group. Factor VIII and tPA-
antigen increased dramatically in the PV subject (+100%, +1000%) in relation to the 
comparison group (+22.9 ± 8.7%, +108 ± 78%) after exercise. Pre-exercise PAI-1 was 
lower in the PV subject and also decreased slightly more (-100%) in response to exercise 
than the comparison group (-43 ± 67%). CONCLUSIONS: Factor VIII, tPA-antigen, and 
PAI-1 responses to exercise are more dramatic in a Polycythemia Vera patient than in 












Chapter I: Introduction 
Polycythemia Vera is a rare myeloproliferative neoplasm in which the bone 
marrow produces too many blood cells due to a mutation within the bone marrow. Red 
blood cells are mainly affected, however an overproduction of platelets and leukocytes 
may also be associated with this blood disorder. The most prevalent mutation is in the 
protein JAK2, which plays a role in cell growth. The JAK2 V617F mutation is seen in 
95% of cases. Polycythemia is mainly diagnosed in males over age 60, however the 
disorder may occur at any age in both males and females. The incidence rate for this 
disorder in females aged 20-34 years is .04 per 100,000.6 Risks associated with 
Polycythemia include thrombotic events such as blood clots and ischemia, splenomegaly, 
and progression to other blood disorders.12 Simple treatments for mild cases consist of 
phlebotomies to maintain hematocrit between 40-45% and a daily 81 mg aspirin.18 Since 
this disorder is very uncommon, especially for young people, there is a lack of research 
on the subject. 
Polycythemia Vera increases the risk for blood clots due to high hematocrit levels 
and a possible high number of platelets, which creates more viscous blood. Although 
high hematocrit levels have not been proven to be a direct cause for thrombotic events, 
previous studies have found strong correlations between hematocrit level and clot risk.17 
The Tromsø study recruited 13714 women and 12394 men as subjects in 1994-5. After 
12.5 years of follow-up, 447 venous thromboembolic events had occurred within the 
sample population. Compared to an age-adjusted hazard ratio of 1.0 for hematocrit <39% 
in women and <43% in men, the hazard ratio for unprovoked VTE with hematocrit ≥42% 
in women and ≥46% in men was 1.62 and 2.37, respectively.4 During exercise, 
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hematocrit levels increase due to a loss of plasma volume13; therefore, risks associated 
with high hematocrit levels in those with Polycythemia Vera may be exacerbated if 
combined with exercise. 
In addition to increasing blood viscosity by increasing hematocrit, exercise also 
independently alters hemostasis by acutely increasing coagulation potential and 
fibrinolysis.10 Markers of coagulation potential that increase with exercise include 
Thrombin anti-thrombin3, Factor VIII2, and platelet activation8. Fibrinolytic potential is 
also increased during acute exercise as evidenced by increases in tissue plasminogen 
activator (tPA) activity11 and a decrease in the main circulating inhibitor of tPA, 
plasminogen activator inhibitor (PAI-1). tPA-antigen also increases in proportion to tPA 
activity during exercise15. Although markers of fibrinolysis increase along with markers 
of coagulation potential, fibrinolysis decreases at a faster rate in the post-exercise 
period14, which thereby increases potential for thrombosis. Thus, a multitude of variables 
can contribute to clotting risks during and after exercise that may lead to life-threatening 
ischemic events. This increased risk for the general population may be enhanced in a 
person with polycythemia vera. Since this disorder is typically seen in older male 
populations, little to no research exists on the complications of exercise in a young, 
active, female with polycythemia vera. This lack of research is most likely due to the 
minimal amount of available subjects and the reduced ability of the elderly with 
Polycythemia Vera to perform strenuous exercise. 
A previous study simulated Polycythemia by infusion of erythrocytes (60% 
hematocrit) in 5 heat-acclimated male subjects and analyzed the effects of hydration and 
exercise on thermoregulation. Each subject completed four heat stress tests: pre and post-
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infusion in a euhydrated state and pre and post-infusion in a hypohydrated state. The heat 
stress tests consisted of two trials of a 45-minute walk with a 15-minute rest in a hot (35 
degrees C and 45% humidity) environment. Interestingly, simulated Polycythemia Vera 
resulted in a thermoregulatory advantage in both a euhydrated and hypohydrated state as 
post-infusion responses increased sweating rate, decreased core body temperature, and 
increased plasma volume.16 However, because this study simply increased RBC count in 
otherwise healthy people, the comparative exercise response in people who have the 
chronic form of Polycythemia is unknown. Polycythemia Vera may consist of elevated 
platelet counts in addition to high hematocrit and in turn may cause different hemostatic 
responses than solely erythrocyte injection. Exercise acutely increases platelet activation, 
which may be intensified with the presence of an increased platelet count. Therefore, the 
simulated Polycythemia study may not be representative of the chronic polycythemia 
population. Rather, this study supported the thermoregulatory advantages of blood 
doping. Thus, there is a paucity of research on exercise responses in patients with 
Polycythemia Vera. 
Understanding the risks associated with Polycythemia is important in relation to 
exercise and other environments that increase thrombosis. Further information is 
necessary in determining the magnitude of these risks, as blood clots are a serious 
medical condition that can lead to other complications such as heart attacks and strokes.12 
Since the increased risks with Polycythemia may be unavoidable, it is important to gather 
information on the responses to exercise. The purpose of this study is to create new 
information and analyze the effects of Polycythemia Vera on clotting factors after 
exercise in a young female diagnosed with Polycythemia compared to subjects without 
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the blood disorder. Further knowledge about this topic may lead to other remedies and 

























Chapter II: Methods 
Participants: The subjects in this study will consist of 10 college-aged, female runners 
(self-reporting >15 miles per week). The student researcher will be participating as the 
Polycythemia Vera subject, while the other subjects will be healthy adults without 
Polycythemia Vera. All subjects will be informed of the procedures and will give 
informed consent to participate. Subjects will be recruited by word of mouth around JMU 
and the greater Harrisonburg area. Participants will be at least 18 years of age. Deception 
will not be used among the participants in this study. 
Exercise Testing: Prior to testing, all subjects will start this research study by being 
assigned an appropriate amount of fluid to ingest per day (42.9mL/kg of body weight) for 
a week.5 Following the week of controlled hydration, each subject will run an 
incremental treadmill test in a controlled environment between 7 and 9 a.m. The treadmill 
test will begin at 2.5 mph and increase 0.5 mph every minute until 6.0 mph; the speed 
will then remain constant as the grade increases by 3% every minute until volitional 
exhaustion. Oxygen uptake will be monitored using a metabolic cart and a heart rate 
monitor will be used to gather heart rate data.  
Blood sampling, assays:  Prior to the treadmill test, participants will rest in a semi-
recumbant position for 15 minutes.  Following this rest period, 10 mL of blood will be 
drawn from an antecubital vein using assumed venipuncture.  All blood samples will be 
obtained by either Dr. Womack or a student/faculty member that’s been appropriately 
trained via procedures approved by the Human Performance Laboratory.  The protocol 
for becoming trained and approved for venipuncture is listed in Appendix C.  Samples 
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will be obtained in an identical manner (except for the 15 minute rest period) 
immediately post-exercise.  Hematocrit and hemoglobin levels will be measured from the 
whole blood samples using a Hemocue automated analyzer.  The remainder of the blood 
samples will be centrifuged immediately for 20 minutes at 1,500xg and 4C to obtain 
platelet-poor plasma, and then frozen and stored at -20C until assayed. Plasma 
concentrations of factor VIII levels, tPA-antigen, and PAI-1 activity will be determined 
using commercially available ELISA kits (VisuLize® Ontario, Canada; Eagle 
Bioscience, Inc, Nashua, New Hampshire) according to manufacturer specifications. 
 
Risks/Benefits:  With strenuous activity, there is potential for muscle or joint soreness, 
and a slight risk of more serious muscular or cardiovascular injury such as muscle strain 
or sprain, ligament damage, heart attack or stroke.  The overall risk of strenuous activity 
(including both low- and high-risk participants) is approximately six cardiac events per 
10,000 tests, or 0.06%.  The risk of a complication requiring hospitalization (including 
non-cardiac problems) is ≤ 0.2%. Risks of blood drawing may include discomfort, 
bruising, and, in rare instances, infection, lightheadedness, and fainting. In order to 
mitigate these exercise related risks, participants will be screened with a health-history 
questionnaire. Only low risk participants, based on the American College of Sports 
Medicine guidelines, will be included in the study. Furthermore, all faculty and students 
engaged in exercise testing in the Human Performance Laboratory are required to have 
current CPR training.  Any evidence of an acute cardiovascular event will prompt the 
research team to activate emergency medical services by calling 911. 
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Alternatives to participating in the study: All participants will be informed that they have 
the right to withdraw from the study at any time without penalty.   
 
Benefits of Research: Due to the limited existing research on Polycythemia Vera, this 
study may provide initial information for further research on the risks of exercise in this 
specific population. Participants will also be given information regarding their 
cardiorespiratory fitness from the exercise test. 
 
Research will take place at the Human Performance Lab in Godwin Hall located on the 
campus of James Madison University. Research will be completed within the Fall 
semester of 2016 (by December 16th, 2016, after receiving IRB approval). 
 
Data Collection: Data will originally be collected on paper data sheets and then will be 
manually entered into a computer spreadsheet. Data, including a flash drive with the 
spreadsheet, will be locked in a file cabinet in Dr. Womack’s office. Dr. Womack and I 
will be the only people to have access to the data. All consent forms will be kept in a 
separate file in a locked file cabinet in Dr. Womack’s office.  Dr. Womack will be the 
only one with access to said file cabinet.  All subjects will be given a subject # which will 
be used as an identifier on all data sheets during the study.  The key for the ID numbers 
will be kept in the same file as the consent forms.  Data will be destroyed by Dr. Womack 




Reporting Procedures: The audience to be reached in the report of this study is the 
Honor’s thesis committee and the Honor’s college. Research will be presented to the 
Department of Kinesiology faculty and students and a possible regional/local exercise 
science conference.  
 
The subjects will receive feedback from the study via email.  
 
Data Analysis 
Due to the limited sample size, this study will be treated as a pilot study and will be 
analyzed without statistical comparisons. Hematocrit and clotting factors will be 
compared between each subject before and after exercise. The differences in clotting 
factors between the control subjects will then be compared to the differences in the 
Polycythemia Vera subject. 
 
Experience of the Researcher (and advisor, if student): 
Dr. Christopher J Womack, PhD will be advising me through my first research 
experience with this study. Dr. Womack has over 25 years of research experience and has 
authored or co-authored over 50 papers in peer-reviewed exercise science journals. He is 
a Fellow of the American College of Sports Medicine, the governing body that 







Chapter III: Manuscript 
Introduction 
Polycythemia Vera is a rare myeloproliferative neoplasm in which the bone 
marrow produces too many blood cells due to a mutation within the bone marrow. Red 
blood cells are mainly affected, however an overproduction of platelets and leukocytes 
may also be associated with this blood disorder. The incidence rate for this disorder in 
females aged 20-34 years is 0.04 per 100,000.6 Risks associated with Polycythemia 
include thrombotic events such as blood clots and ischemia, splenomegaly, and 
progression to other blood disorders.21 Simple treatments for mild cases consist of 
phlebotomies to maintain hematocrit between 40-45% and a daily 81 mg aspirin.29 Since 
this disorder is very uncommon, especially for young people, there is a lack of research 
on the subject. 
Although high hematocrit levels have not been proven to be a direct cause for 
thrombotic events, previous studies have found strong correlations between hematocrit 
level and clot risk.27 During exercise, hematocrit levels increase due to a loss of plasma 
volume20; therefore, risks associated with high hematocrit levels in those with 
Polycythemia Vera may be exacerbated if combined with exercise. In addition to 
increasing blood viscosity by increasing hematocrit, exercise also independently alters 
hemostasis by acutely increasing coagulation potential and fibrinolysis.16 Markers of 
coagulation potential that increase with exercise include Thrombin anti-thrombin4, Factor 
VIII2, and platelet activation.12 Fibrinolytic, or clot lysis, potential is also increased 
during acute exercise as evidenced by increases in tissue plasminogen activator (tPA) 
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activity18 and a decrease in the main circulating inhibitor of tPA, plasminogen activator 
inhibitor (PAI-1). tPA-antigen also increases in proportion to tPA activity during 
exercise.25 Although markers of fibrinolysis increase along with markers of coagulation 
potential, fibrinolysis decreases at a faster rate in the post-exercise period24, which 
thereby increases potential for thrombosis. Thus, a multitude of variables can contribute 
to clotting risks during and after exercise that may lead to life-threatening ischemic 
events. This increased risk for the general population may be enhanced in a person with 
Polycythemia Vera due to the elevated number of platelets activated by exercise.14 Since 
this disorder is typically seen in older male populations, little to no research exists on the 
complications of exercise in a young, active, female with Polycythemia Vera. This lack 
of research is most likely due to the minimal amount of available subjects and the 
reduced ability of the elderly with Polycythemia Vera to perform strenuous exercise. 
A previous study simulated Polycythemia Vera by infusion of erythrocytes (60% 
hematocrit) in five heat-acclimated male subjects. Interestingly, simulated Polycythemia 
Vera resulted in a thermoregulatory advantage in both a euhydrated and hypohydrated 
state as post-infusion responses increased sweating rate, decreased core body 
temperature, and increased plasma volume.26 However, because this study simply 
increased RBC count in otherwise healthy people, the comparative exercise response in 
people who have the chronic form of Polycythemia is unknown. Polycythemia Vera may 
consist of elevated platelet counts in addition to high hematocrit and in turn may cause 
different hemostatic responses than solely erythrocyte injection. Exercise acutely 
increases platelet activation, which may be intensified with the presence of an increased 
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platelet count. Therefore, the simulated Polycythemia study may not be representative of 
the chronic Polycythemia population.  
Understanding the risks associated with Polycythemia is important in relation to 
exercise and other environments that increase thrombosis. Further information is 
necessary to determine the magnitude of these risks, as blood clots are a serious medical 
condition that can lead to other complications such as heart attacks and strokes.12 Since 
the increased risks with Polycythemia may be unavoidable, it is important to gather 
information on the responses to exercise. The purpose of this study is to create new 
information and analyze the effects of Polycythemia Vera on clotting factors after 
exercise in a young female diagnosed with Polycythemia compared to subjects without 
the blood disorder. Further knowledge about this topic may lead to other remedies and 















Participants: The subjects in this study consisted of 6 college-aged, female runners (self-
reporting >15 miles per week). The student researcher participated as the Polycythemia 
Vera subject, while the other subjects in the control group were healthy adults without 
Polycythemia Vera. The control group had a mean height, weight, and VO2max of 168.4 
± 7.9 cm, 67.2 ± 11.0 kg, and 43.2 ± 4.3 ml/kg/min respectively. Mean age for the control 
group was 21 years. The Polycythemia Vera subject’s height, weight, and VO2max were 
165.1 cm, 55.8 kg, and 60 ml/kg/min. The Polycythemia Vera subject was 21 years old. 
All subjects were informed of the procedures and gave informed consent to participate. 
Subjects were recruited by word of mouth around JMU and the greater Harrisonburg 
area.  
Exercise Testing: Prior to testing, all subjects were assigned an appropriate amount of 
fluid to ingest per day (42.9mL/kg of body weight) for a week.9 Following the week of 
controlled hydration, each subject ran an incremental treadmill test in a controlled 
environment between 8 and 10 a.m. The treadmill test began at 2.5 mph and increased 0.5 
mph every minute until 6.0 mph; the speed then remained constant as the grade increased 
by 3% every minute until volitional exhaustion. Oxygen uptake was monitored using a 
Moxus metabolic cart and a heart rate monitor was used to gather heart rate data. All 
subjects were fasted for a minimum of 10 hours prior to testing and abstained from 
alcohol 24 hours prior to testing.  
Blood sampling, assays:  Prior to the treadmill test, participants rested in a semi-
recumbant position for 15 minutes.  Following this rest period, 10 mL of blood was 
drawn from an antecubital vein using assumed venipuncture. Samples were obtained in 
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an identical manner (except for the 15 minute rest period) immediately post-exercise.  
Hematocrit and hemoglobin levels were measured from the whole blood samples using a 
Hemocue automated analyzer.  The remainder of the blood samples were centrifuged 
immediately for 20 minutes at 1,500xg and 4C to obtain platelet-poor plasma, and then 
frozen and stored at -20C until assayed. Plasma concentrations of factor VIII levels, 
tPA-antigen, and PAI-1 activity were determined using commercially available ELISA 
kits (VisuLize® Ontario, Canada; Eagle Bioscience, Inc, Nashua, New Hampshire) 




















The comparison group completed the maximal treadmill test with a mean 
VO2max of 43.2 ± 4.3 ml/kg/min while the Polycythemia Vera (PV) subject achieved a 
VO2max of 60 ml/kg/min. Pre- and Post-exercise hemostatic variables for the PV patient 
and the comparison group are displayed in Table 1. The comparison group had a mean 
pre-exercise hematocrit and hemoglobin of 40.5 ± .8% and 13.38 ± .97 g/dl respectively. 
Pre-exercise hematocrit and hemoglobin in the PV patient was 44.5% and 15.15 g/dl. 
Hematocrit in both groups increased in response to exercise similarly. Hemoglobin in the 
PV subject increased less (+6.9%) than the comparison group (+11.51 ± 1.42%) after 
exercise. The PV subject’s pre-exercise Factor VIII (0.64) was similar to the comparison 
group pre-exercise (0.70 ± 0.11). However, the PV subject had a larger increase (+100%) 
than the comparison group following exercise (+22.9 ± 8.7%). Pre-exercise tPA-antigen 
was similar in the PV subject (1.1) and the comparison group (1.00 ± 0.31). Post-exercise 
tPA-antigen in the PV subject increased dramatically (+1000%) relative to the 
comparison group (+108 ± 78%). Pre-exercise PAI-1 was lower in the PV subject (0.56) 
than the comparison group (3.21 ± 2.22). Post-exercise PAI-1 in the PV subject had a 








Table 1. Mean (±SD) for all hemostatic variables for the Polycythemia Vera patient and the  
comparison group. 
Variable Polycythemia Vera Patient Comparison Group (mean ± 
SD) 
Factor VIII   
Pre-Exercise .64 .70 ± .11 
Post-Exercise 1.28 .86 ± .19 
% change with 
exercise 
100% 22.9 ± 8.7% 
tPA-antigen   
Pre-Exercise 1.13 1.00 ± .31 
Post-Exercise 12.50 2.08 ± .86 
% change with 
exercise 
1000% 108 ± 78% 
PAI-1   
Pre-Exercise 0.55 3.21 ± 2.22 
Post-Exercise 0 1.83 ± 1.60 
% change with 
exercise 
-100% -43 ± 67% 
Hematocrit   
Pre-Exercise 44.5 40.5 ± .8 
Post-Exercise 47.5 43.8 ± 2.2 
% change with 
exercise 
6.7% 8.15 ± .57% 
Hemoglobin   
Pre-Exercise 15.15 13.38 ± .97 
Post-Exercise 16.2 14.92 ± .76 
% change with 
exercise 














As expected, the Polycythemia Vera subject started with higher pre-exercise 
hematocrit levels than the control group. Hematocrit increased in the Polycythemia 
subject at a similar degree to the control group in response to exercise. While artificially 
increasing hematocrit (e.g. blood doping) has resulted in enhanced aerobic performance, 
naturally occurring elevated hematocrit levels may have a negative effect on aerobic 
fitness.5, 6 A study of 77 soccer players in France separated each player into specific 
quintiles based on their hematocrit. The first quintile contained those with the lowest 
hematocrit (38.7 ± .8) while the 5th quintile contained players with the highest hematocrit 
(45.5 ± .3). The 2nd, 3rd, and 4th quintiles contained players with a mean hematocrit of 
42.3 ± .2. The players in the 1st quintile proved to have a higher aerobic fitness level than 
the players in every other quintile, thus suggesting an inverse relationship between 
hematocrit and fitness. This inverse relationship may be attributable to a hemodilution 
effect associated with training. Ferritin also has a negative correlation with hematocrit, 
which could be a factor contributing to a lower aerobic fitness level in those with high 
hematocrit.5 Patients with Polycythemia Vera typically have lower ferritin levels30 and 
therefore, the higher VO2max achieved by the Polycythemia Vera subject may not be due 







Pre-exercise Factor VIII levels for both the Polycythemia Vera subject and 
control group were similar. The Polycythemia Vera subject’s post-exercise levels 
exhibited a larger increase than the control group. This may be explained by the higher 
intensity and duration of exercise achieved by the Polycythemia Vera subject.1 There is 
also speculation of a chronically activated coagulation cascade in patients with 
Polycythemia Vera, specifically the intrinsic pathway.8 Factor VIII is an intrinsic 
pathway factor that originates from platelets.3 With the combination of a chronically 
activated intrinsic pathway and elevated levels of platelets associated with Polycythemia 
Vera, an increased production or activation of Factor VIII could be associated with these 
Polycythemia Vera complications.   
 
tPA antigen 
tPA-antigen in the Polycythemia Vera subject was similar to the control group 
before exercise. Post-exercise tPA-antigen, however, increased dramatically in the 
Polycythemia Vera subject compared to the control group. Although tPA is positively 
correlated with exercise intensity28 and may explain a portion of the greater increase, the 
large difference between groups would suggest other mechanisms contributing to the 
marked increase observed in the Polycythemia Vera patient.  
Along with increased red blood cells, Polycythemia Vera may also be 
accompanied with elevated platelet levels. In Polycythemia Vera patients with the 
JAK2V617F mutation, platelet thrombin generation potential was significantly elevated 
compared to control groups.23 Exercise also enhances thrombin generation, which can 
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lead to platelet activation.17 With an increased presence of thrombin and activated 
platelets, clot formation may increase due to the conversion of fibrinogen to fibrin.11 
Since fibrin is necessary for the creation of plasmin by tissue plasminogen activator22, 




Pre-exercise PAI-1 in the Polycythemia Vera subject was lower than the control 
group, which contradicts previous findings of elevated PAI-1 in Polycythemia Vera 
subjects.7 PAI-1 can also be significantly influenced by BMI. Although the protocol did 
not collect BMI specifically, the Polycythemia Vera subject had the lowest BMI 
calculated from height and weight. In agreement with previous research, a lower BMI 
correlates with lower PAI-1.31 
 
Implications 
Since high Factor VIII levels may increase risk for thrombotic events15, 19, a low PAI-1 
level may be important in attenuating these risks. The high tPA-antigen response to 
exercise in the Polycythemia Vera subject may represent increased fibrinolytic response 
to offset the increased coagulation potential evidenced during exercise. High Factor VIII 
in response to exercise increases the risk for thrombosis and other related events, 
however the large increase in post-exercise tPA-antigen may be able to attenuate these 
risks. Since fibrinolysis tends to decrease at a faster rater than coagulation potential, 
Polycythemia Vera patients may be at an increased risk for thrombotic events after 
 
26 
exercise due to a larger production of Factor VIII, however the dramatically high tPA-
antigen response may have an acute protective affect during and immediately after 
exercise. Extensive research must be conducted before these findings can be generalized 
to the whole Polycythemia Vera population. Future research is also necessary on this 
disorder in order to find effective treatment during exercise. The current treatment for 
mild Polycythemia Vera is a daily 81mg aspirin and phlebotomy p.r.n., however previous 
research indicates aspirin may not be effective in the context of exercise.13  
 
Limitations: 
There are many limitations to these findings since this study only included one 
Polycythemia Vera subject. Perhaps researching subjects with similar VO2max and BMI 
values may have led to more comparable results. The mean results in the control group 
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Consent to Participate in Research 
Identification of Investigators & Purpose of Study   
You are being asked to participate in a research study conducted by Allison Huschke 
and Christopher J. Womack, Ph.D. from James Madison University.  The purpose of 
this study is to determine if a person with Polycythemia Vera is more likely to have 
higher clotting potential after exercise than a healthy adult without the blood 
disorder.  
Potential Risks & Benefits 
If you choose to participate in this study, you will perform one maximal treadmill 
test. With strenuous exercise, the investigator perceives a potential for muscle or 
joint soreness, and a slight risk of more serious muscular or cardiovascular injury 
such as muscle strain or sprain, ligament damage, heart attack or stroke. In healthy 
individuals, the risk of death during vigorous exercise has been estimated at 1 death 
per year for every 18,000 individuals. In order to mitigate these exercise related 
risks, participants will be screened with a health-history questionnaire. Only low 
risk participants, based on the American College of Sports Medicine guidelines, will 
be included in the study.  Furthermore, all faculty and students engaged in exercise 
testing in the Human Performance Laboratory are required to have current CPR 
training.  Any evidence of an acute cardiovascular event will prompt the research 
team to activate emergency medical services by calling 911. 
 
Potential benefits from participation in this study include:  
 
VO2max results and the opportunity to help increase research conducted on Polycythemia 
Vera. 
Research Procedures 
Should you decide to participate in this research study, you will be asked to sign this 
consent form once all your questions have been answered to your satisfaction.  This 
study consists of one week of controlled hydration as well as one maximal treadmill 
test. You will also be subjected to blood tests both before and after each trial. Your 
heart rate will be monitored by a monitor that wraps around your chest.  
 
Blood Sampling: We will obtain about 10 ml of blood (about 2 teaspoons) prior to 
and immediately after the treadmill test in order to determine the potential of your 




The results of this study will be presented to the Department of Kinesiology faculty 
and students and a possible regional/local exercise science conference. The results 
of this project will be coded in such a way that your identity will not be attached to 
the final form of this study.  The researcher retains the right to use and publish non-
identifiable data.  However, you can ask that your data be removed from the study at 
any point prior to presentation and publication. While individual responses are 
confidential, aggregate data will be presented representing averages or 
generalizations about the responses as a whole. All data will be stored in a secure 
location accessible only to the researchers.  Data will be destroyed within a year 
after research is completed. Final results will be made available to you upon 
request. 
Participation & Withdrawal  
Your participation is entirely voluntary.  You are free to choose not to participate.  
Should you choose to participate, you can withdraw at any time without 
consequences of any kind.  Your right to withdraw includes the right to request that 
your blood samples be discarded at any time. 
Questions 
You may have questions or concerns during the time of your participation in this 
study, or after its completion.  If you have any questions about the study, contact 
Allison Huschke at huschkam@dukes.jmu.edu, or Christopher J. Womack, Ph.D. at 
womackcx@jmu.edu or 540-568-6515. 
Giving of Consent 
I have read this consent form and I understand what is being requested of me as a 
participant in this study.  I freely consent to participate.  I have been given 
satisfactory answers to my questions.  The investigator provided me with a copy of 
this form.  I certify that I am at least 18 years of age. 
 
 
   
Name of Participant  (Printed)  Name of Researcher(s)  (Printed) 
   
Name of Participant  (Signed)  Name of Researcher(s)  (Signed) 
   
  Date    Date 
 




For questions about your rights as a research subject, you may contact the chair of 





James Madison University 
Department of Kinesiology 
Health Status Questionnaire 
  
Instructions: Complete each question accurately. All information provided is 
confidential.  
Part I:  General Information  
  
1. Subject # 
  
2. Local Phone                                                 Email: 
____________________________________  
  
3. Gender (circle one)  Male   Female  
  
4. Date of Birth  (Month/ Day/ Year) 
 
Part II: Medical History  
  
5. Circle any that died of heart attack before age 50:  Father  Mother  Brother  
Sister  Grandparent  
   
  
6. Date of last medical exam: _____________ Last physical fitness test: 
_______________  
  
7. Circle operations you have had:  Back   Heart   Kidney   Eyes    Joint    Neck     
Ears     Hernia     
                                        
        Lung     Other ________________  
  
8. Please circle any of the following for which you have been diagnosed or 
treated by a physician or health professional:  
  
Alcoholism     Diabetes       Kidney Problems  
Anemia (sickle cell)   Emphysema      Mental Illness  
Anemia (other)    Epilepsy      Muscular Injury  
Asthma      Eye Problems      Neck Strain  
Back Strain     Gout        Obesity  
Bleeding trait     Hearing Loss      Orthopedic Injuries  
Bronchitis, chronic    Heart Problem      Phlebitis  
Cancer       High Blood Pressure  Rheumatoid arthritis  
Cirrhosis, liver     Hypoglycemia      Stroke  
Concussion     Hyperglycemia     Thyroid problem  
Congenital defect   Infectious Mononucleosis Ulcer  




9. Circle all medications taken in the last six months:  
 
Blood thinner    Epilepsy medication     Nitroglycerin  
Diabetic pill    Heart-rhythm medication   Other __________________  
Digitalis     High-blood pressure medication  
Diuretic     Insulin  
  
10. Any of these health symptoms that occur frequently is the basis for medical 
attention. Circle the  
number indicating how often you have each of the following:  
  
5 = Very often    4 = Fairly often   3 = Sometimes   2 = Infrequently   1= 
Practically never  
  
a. cough up blood     f. chest pain  
    1   2   3   4   5                   1   2   3   4   5  
  
b. abdominal pain     g. swollen joints  
    1   2   3   4   5                     1   2   3   4   5  
  
c. low back pain     h. feel faint  
    1   2   3   4   5                    1   2   3   4   5  
  
d. leg pain       i. dizziness  
    1   2   3   4   5                   1   2   3   4   5  
  
e. arm or shoulder pain   j. breathless on slight exertion  
    1   2   3   4   5                   1   2   3   4   5  
  
Part III: Health Related Behavior  
  
11. Do you smoke?  Yes No  
  




 40 or more   20-39   10-19   1-9  
  
Cigars or pipes only:   
 
 5 or more or any inhaled  less than 5, none inhaled  
  








 1  2  3  4  5  6  7  days per week  
  
15. Can you walk 4 miles briskly without fatigue? Yes No  
  
16. Can you jog 3 miles continuously at a moderate pace without discomfort?  
Yes      No  
  
17. Weight now: __________ lb.  One year ago: __________ lb   Age 21: 











       
 
PROCEDURES/POLICIES FOR VENOUS BLOOD DRAWS 
 
Laboratory faculty, instructors and researchers (including research assistants) 
should complete the following training actions prior to conducting this procedure: 
 
a) Complete all standard lab safety procedures (review CHBS Lab Safety Plan and the HPL 
Safety Protocols and Responsibilities, and complete the Acknowledgement of Safety 
Training Form and HPL Safety Protocols Test)  
b) Compete bloodborne pathogen training (http://www.jmu.edu/bbp/index.shtml)  
c) Review the written procedures below 
d) Receive hands-on training from a trained faculty member (or graduate student who has 
completed training previously), including at least three consecutive successful procedures 
by the trainee 
e) Complete/sign page 2 of this form, and provide a hard-copy to the Lab Director            




1) Prepare all materials ahead of time: needle, plastic Vacutainer holder (screw 
needle into holder ahead of time, and leave cover on needle), rubber 
tourniquet, alcohol swabs, gauze, Vacutainer tubes.  
 
2) Exam gloves are to be worn at all times 
 
3) Subject will have the needle inserted in an antecubital vein while sitting in a 
partially reclined chair. 
 
4) Apply tourniquet firmly to arm around the lower bicep area. 
 
5) Palpate the area on the inside of the elbow joint to find a prominent 
anticubital vein. 
 
6) Prepare the insertion area by wiping thoroughly with an alcohol swab, then 
allow ~30 seconds for any remaining alcohol to evaporate. 
 
7) Remove cover from needle and insert the needle (beveled edge facing up) 
through the skin into the anticubital vein, along the center of the longitudinal 
axis of the vein. 
 
8) Once the needle is in the vein, hold the plastic needle holder steady, and 
press the Vacutainer firmly into the plastic holder (puncturing the seal on the 
Vacutainer, and initiating blood collection).   
 




10) Once the desired amount of blood is obtained, remove the Vacutainer from 
the holder (if you are filling more than one tube, insert a second tube as 
described in # 8). 
 
11) To remove the needle from the vein, quickly withdraw the needle in a 
direction directly opposite to insertion.  Immediately apply sterile gauze to 
the area and apply pressure. 
 
12) Have the subject continue to apply pressure to the area for at least 2 minutes 
to cease bleeding and prevent bruising. 
 
13) Apply a band-aid over top of the gauze. 
 
14) Waste removal: 
a. All sharps (needles, catheter, any glass, hard plastic, etc) must be 
disposed in a red plastic sharps container (Biohazard). 
b. All non-sharps materials that have been in contact (or potentially in 
contact) with blood (gauze, gloves, etc.) must be disposed in a red 
Biohazard bag. 
c. Unsoiled paper wrappers etc. can be disposed in regular trash bins. 
d. Check that all waste has been removed, and the area is entirely clear 
of any waste/blood.   
e. If any blood has spilled in the area (i.e. on chairs, floor, equipment), 
clean thoroughly with germicidal bleach (i.e. Clorox®) and paper 
towels. 
f. If you are supervising students who are performing this technique (i.e. 
for a lab class or study), it is your responsibility to double-check the 





Date of Training Completion:    
 
By signing below, the Trainee is acknowledging that they have completed 
items a, b, c, and d on page 1 of this form.  The Trainer is acknowledging 
that they have provided hands-on training of this procedure for the 
Trainee, and have witnessed the trainee perform the procedures 
successfully on at least three consecutive occasions. 
 
 







Name     Signature   Date 
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